{
    "nct_id": "NCT01436045",
    "title": "A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.",
    "status": "COMPLETED",
    "last_update_time": "2015-09-25",
    "description_brief": "The purpose of this study is to investigate the effect of the rapidly acting intranasal insulin derivative (glulisine) on memory and cognition in 12 patients suffering from mild-moderate Alzheimer's Disease (AD) using a double-blind placebo-controlled single dose study. This study will further assess safety of insulin glulisine as well as the effects of this drug on olfaction.",
    "description_detailed": "A single center, phase II randomized, double-blind, placebo-controlled, cross-over study designed to assess the efficacy and safety of intranasally (IN) delivered insulin glulisine versus placebo in patients aged 65-85 with mild-moderate Alzheimer's Disease (AD). Twelve AD subjects (six female and six male) will be randomized to receive a single dose of either 20 IU/IN insulin glulisine or placebo using the MAD 300 device.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Insulin Glulisine, Then Placebo",
                    "description": "A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.\n\nInsulin glulisine (5 minutes), Washout (1 week), Placebo (5 minutes)\n\nInsulin glulisine: Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)\n\nPlacebo: Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)"
                },
                {
                    "id": "FG001",
                    "title": "Placebo, Then Insulin Glulisine",
                    "description": "A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.\n\nPlacebo (5 minutes), Washout (1 week), Insulin Glulisine (5 minutes)\n\nInsulin glulisine: Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)\n\nPlacebo: Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "6"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "6"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "All Study Partipants",
                    "description": "Participants who received either intranasal glulisine (0.10 milliliter (mL) in each nostril, 20 IU total) or placebo (0.10 mL in each nostril) at the 2nd or 3rd study visit."
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "12"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "72",
                                            "spread": "4.6"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "3"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "9"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "12"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Mini Mental State Examination (MMSE)",
                    "description": "MMSE scale is 0 to 30. Lower scores indicate more severe cognitive impairment. Higher scores (27-30) indicate normal cognition.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "22.17",
                                            "spread": "2.62"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "University of Pennsylvania Smell Inventory Test (UPSIT)",
                    "description": "UPSIT is used to test the function of an individual's olfactory system. The first 20 items (out of 40) were used. Range of 0-20. Lower scores indicate a lower functioning olfactory system. Higher scores indicate normal olfactory functioning.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "11.8",
                                            "spread": "2.52"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Cognitive Performance",
                    "description": "The results are presented as a mean number of correct responses for each cognitive assessment.\n\nFor each of these, a lower number correct is indicative of a higher cognitive deficit.\n\nRanges are as follows: RBANS List Learning (0-40), RBANS Story Memory (0-24), RBANS Figure Copy (0-20), RBANSLine Orientation (0-20), RBANS Semantic Fluency (0-unlimited), RBANS List Recall (0-10), RBANS List Recognition (0-20), RBANS Story Recall (0-12), RBANS Figure Recall (0-20), Digit Span Forward (0-16), Digit Span Backward (0-16), Boston Naming (0-15).",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "mean total correct responses",
                    "timeFrame": "20 minutes post-intranasal administration",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Post-Insulin Glulisine",
                            "description": "Results of cognitive assessment after intranasal treatment with Insulin Glulisine."
                        },
                        {
                            "id": "OG001",
                            "title": "Post-Placebo",
                            "description": "Results of cognitive assessment after intranasal treatment with Placebo."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "12"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "12"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "RBANS List Learning",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "15.92",
                                            "spread": "1.32"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "16.67",
                                            "spread": "2.02"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "RBANS Story Memory",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8.58",
                                            "spread": "1.17"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "8.41",
                                            "spread": "1.55"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "RBANS Figure Copy",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "16.58",
                                            "spread": "0.98"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "16.92",
                                            "spread": "3.42"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "RBANS Line Orientation",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "14.25",
                                            "spread": "0.97"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "12.25",
                                            "spread": "1.38"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "RBANS Semantic Fluency",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "12.25",
                                            "spread": "1.38"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "12.5",
                                            "spread": "1.75"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "RBANS List Recall",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.83",
                                            "spread": "0.42"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.0",
                                            "spread": "0.51"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "RBANS List Recognition",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "14.92",
                                            "spread": "0.69"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "14.75",
                                            "spread": "0.97"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "RBANS Story Recall",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.12",
                                            "spread": "0.96"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.33",
                                            "spread": "0.90"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "RBANS Figure Recall",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.83",
                                            "spread": "1.84"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "4.92",
                                            "spread": "1.59"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Digit Span Forward",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "9.42",
                                            "spread": "0.50"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "9.0",
                                            "spread": "0.44"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Digit Span Backward",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "5.58",
                                            "spread": "0.45"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "5.75",
                                            "spread": "0.49"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Boston Naming Test",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "11.75",
                                            "spread": "1.05"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "11.75",
                                            "spread": "1.10"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Response to intranasal Insulin Gluiline \\[(result post-insulin - result post-placebo)/(result post-placebo)\\] x 100%",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "<0.05",
                            "pValueComment": "RBANS Line Orientation",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Percent Change",
                            "paramValue": "-15.7",
                            "ciNumSides": "TWO_SIDED",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "7.0",
                            "estimateComment": "Response to intranasal Insulin Glulisine \\[(result post-insulin - result post-placebo)/(result post-placebo)\\] x 100%"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Olfactory Function",
                    "description": "The Sniff Magnitude Test (SMT) measures olfactory function not influenced by cognitive problems (minimal dependence on language, cognitive ability, memory, and odor naming ability). Sniff magnitude ratios are calculated as a ratio of sniff magnitudes (area under the sniff curve). Lower sniff magnitude ratios indicate more impairment.\n\n\\[average sniff magnitude of malodor/average sniff magnitude to a null odor\\]",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "ratio of area under the sniff curve",
                    "timeFrame": "60 minute post intranasal administration",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Post-Insulin Glulisine",
                            "description": "Results of cognitive assessment after intranasal treatment with Insulin Glulisine."
                        },
                        {
                            "id": "OG001",
                            "title": "Post Placebo",
                            "description": "Results of cognitive assessment after intranasal treatment with Placebo."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "12"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "12"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.5",
                                            "spread": "0.15"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.33",
                                            "spread": "0.19"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Trails B - Seconds",
                    "description": "The results are presented as the number of seconds to complete Trails B. For each of these, a higher number of seconds is indicative of a higher cognitive deficit.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "mean seconds",
                    "timeFrame": "20 minutes post-intranasal administration",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Post-Insulin Glulisine",
                            "description": "Results of cognitive assessment after intranasal treatment with Insulin Glulisine."
                        },
                        {
                            "id": "OG001",
                            "title": "Post-Placebo",
                            "description": "Results of cognitive assessment after intranasal treatment with Placebo."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "12"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "12"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "166.83",
                                            "spread": "20.82"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "177.25",
                                            "spread": "21.65"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Trails B - Errors",
                    "description": "The results are presented as the mean sum of the errors during the Trails B assessment For each of these, a higher number of errors is indicative of a higher cognitive deficit.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "mean number of errors",
                    "timeFrame": "20 minutes post-intranasal administration",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Post-Insulin Glulisine",
                            "description": "Results of cognitive assessment after intranasal treatment with Insulin Glulisine."
                        },
                        {
                            "id": "OG001",
                            "title": "Post-Placebo",
                            "description": "Results of cognitive assessment after intranasal treatment with Placebo."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "12"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "12"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.17",
                                            "spread": "0.27"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.08",
                                            "spread": "0.31"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "Difference in errors \\[result post-insulin - result post-placebo\\]",
                            "testedNonInferiority": false,
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "<0.05",
                            "statisticalMethod": "t-test, 2 sided",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.92",
                            "ciNumSides": "TWO_SIDED",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.26"
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "All Study Partipants",
                    "description": "Participants who received either intranasal glulisine (0.10 mL in each nostril, 20 IU total) or placebo (0.10 mL in each nostril) at the 2nd or 3rd study visit.",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 12,
                    "otherNumAffected": 0,
                    "otherNumAtRisk": 12
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": true
            },
            "pointOfContact": {
                "title": "Michael H Rosenbloom, MD",
                "organization": "HealthPartners Institute for Education and Research",
                "email": "michael.h.rosenbloom@healthpartners.com",
                "phone": "6512547900"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "insulin glulisine (rapid-acting insulin analog; administered intranasally in this trial)"
    ],
    "placebo": [
        "saline/placebo (intranasal)"
    ],
    "explanation_target": [
        "Reason: The intervention is insulin glulisine, a rapid-acting insulin analogue being delivered intranasally to test effects on memory and cognition rather than to target classical AD pathology (amyloid or tau). Insulin glulisine is a rapid-acting insulin analog (brand: Apidra). \ue200cite\ue202turn1search0\ue201",
        "Act: The trial description (NCT01436045 / single-dose, double-blind, placebo-controlled intranasal glulisine in mild\u2013moderate AD) and related single-dose pilot publications show the drug was used to attempt acute cognitive/memory improvement and to assess safety/olfaction, not as an anti-amyloid or anti-tau biologic. Intranasal rapid-acting glulisine has been tested in small AD/MCI studies for memory effects. \ue200cite\ue202turn0search3\ue202turn0search1\ue201",
        "Reflect: Given the drug is an insulin analogue (a peptide biologic) but the intended effect in these trials is acute cognitive/memory enhancement via modulation of CNS insulin signaling (not targeting amyloid/tau pathologic species for disease modification), the correct category is 'cognitive enhancer'. Systematic reviews/meta-analyses of intranasal insulin in AD/MCI likewise frame these interventions as aiming to improve memory/cognition. \ue200cite\ue202turn0search5\ue202turn0search4\ue201"
    ],
    "agent_type": "L) Growth Factors and Hormones",
    "explanation_agent": [
        "Reason: The intervention is insulin glulisine (Apidra), a rapid\u2011acting insulin analogue delivered intranasally to modulate central nervous system insulin signaling with the goal of acute cognitive/memory improvement rather than targeting amyloid or tau pathology. \ue200cite\ue202turn0search0\ue202turn0search8\ue201",
        "Act: Extracted trial details \u2014 drug: insulin glulisine (rapid\u2011acting insulin analog, brand Apidra) administered intranasally in a randomized, double\u2011blind, placebo\u2011controlled design to test effects on memory/cognition and safety/olfaction (NCT01436045 and related pilot/phase II reports). These trials and systematic reviews/meta\u2011analyses frame intranasal insulin as an approach to boost brain insulin signaling and cognition in AD/MCI. \ue200cite\ue202turn0search0\ue202turn0search8\ue202turn0search5\ue202turn0search1\ue201",
        "Reflect: Insulin is a hormone/growth\u2011factor family member whose exogenous delivery is intended to modulate hormone signaling in the brain; under CADRO, interventions that act via hormones/growth\u2011factor pathways best map to 'L) Growth Factors and Hormones'. An alternative plausible mapping could be 'J) Metabolism and Bioenergetics' (insulin affects glucose metabolism) or 'M) Synaptic Plasticity/Neuroprotection' (insulin influences synaptic function), but the most specific CADRO category for a hormone therapy is L. Supporting sources: the trial record, pilot publications, and systematic reviews/meta\u2011analyses of intranasal insulin in AD/MCI. \ue200cite\ue202turn0search0\ue202turn0search8\ue202turn0search7\ue202turn0search3\ue201",
        "Web search results cited (summary):",
        "- Clinical trial record NCT01436045: Safety and Effectiveness Study of Intranasal Insulin Glulisine in mild\u2013moderate AD (single\u2011dose crossover; 20 IU intranasal glulisine vs saline). \ue200cite\ue202turn0search0\ue201",
        "- Pilot single\u2011dose study: intranasal rapid\u2011acting insulin (glulisine) in ApoE4 carriers with mild\u2013moderate AD (safety and acute cognition endpoints). \ue200cite\ue202turn0search8\ue201",
        "- Phase II randomized study of intranasal glulisine in amnestic MCI and probable mild AD (longer dosing schedules reported in the literature). \ue200cite\ue202turn0search5\ue201",
        "- Systematic reviews and meta\u2011analyses summarizing intranasal insulin trials in AD/MCI and describing effects on memory/verbal recall and rationale for targeting brain insulin signaling. \ue200cite\ue202turn0search1\ue202turn0search3\ue201"
    ]
}